Skip to content

Author

N. Chalasani

6 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Nov 2026

Long‐Term Survival of Liver Transplantation in Alcohol‐Associated Liver Disease: Insights From National Claims Data

ABSTRACT Background Alcohol‐associated liver disease (ALD) is a leading indication for liver transplantation (LT) in the United States. While post‐transplant outcomes are well established, the relative survival benefit of LT compared to non‐LT remains underdefined. Methods Using Optum's de‐identified Clinformatics Data...

Wan-Zhu Tu, L. Nephew, Yi-Ning Li et al. · 0 citations
Open access Oct 2026

Saroglitazar improves hepatic steatosis and liver enzymes in women with polycystic ovary syndrome and MASLD: A multicenter, double-blind, placebo-controlled study.

BACKGROUND AND AIMS Polycystic ovary syndrome (PCOS) is the leading endocrine disorder in reproductive-age women. Metabolic dysfunction-associated steatotic liver disease (MASLD) is common in women with PCOS, but they are underrepresented in MASLD therapeutic trials. We evaluated the safety and efficacy of saroglitazar...

Niharika R. Samala, J. González-González, Robert A. Jenders et al. · 0 citations
Oct 2026

Trends in the etiologies and outcomes of idiosyncratic drug-induced liver injury in the united states: The DILIN prospective registry, 2004 to 2024.

BACKGROUND AIMS Idiosyncratic drug-induced liver injury (DILI) is an infrequent cause of liver disease. The aim of this study is to report on temporal changes in the etiology and outcomes of idiosyncratic DILI in the United States DILIN Prospective study. METHODS The presenting clinical features and outcomes of conse...

R. Fontana, N. Chalasani, P. Hayashi et al. · 0 citations
Sep 2026

Risk Factors and Definition of Younger-Onset Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) Cirrhosis.

BACKGROUND & AIMS Cirrhosis from metabolic dysfunction-associated steatotic liver disease (MASLD) usually develops with advancing age, yet a subset of patients presents at younger ages. We examined genetic and metabolic factors associated with younger-onset MASLD cirrhosis. APPROACH AND RESULTS Adults with biopsy-pro...

Veeral H. Ajmera, Linus Schwantes-An, Luis Antonio Díaz et al. · 0 citations
Open access Oct 2026

Age‐Specific Associations of Polygenic Risk Scores With Advanced Fibrosis and Histological Activity in Biopsy‐Proven MASLD

The genetic susceptibility to MASLD histological severity remains incompletely defined. We assessed the associations between recently developed genome‐wide association studies–derived polygenic risk scores (PRSs) and advanced fibrosis in MASLD. We also evaluated PRSs' associations with histological activity and selecte...

S. Gawrieh, Jing-Yi Tan, Xiu-Qing Guo et al. · 0 citations
Meta-analysis Open access Sep 2026

Conserved hepatic RNA signatures across multiple cohorts reveal novel mechanistic clues for advanced fibrosis in human MASLD

Background: Fibrosis development in patients with metabolic dysfunction–associated steatotic liver disease (MASLD) is a key indicator of disease progression and clinical outcome. Bulk and single-cell transcriptomics on human tissue have advanced understanding of fibrosis progression, but interstudy heterogeneity and li...

Jessica L. Maiers, Tie-Bing Liang, Tingbo Guo et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.